Sinopharm CNBG COVID-19 vaccine
id:
sinopharm-cnbg-covid-19-vaccine-253-15699681
title:
Sinopharm CNBG COVID-19 vaccine
text:
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute, a subsidiary of CNBG of Sinopharm. They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein. It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.
brand slug:
wiki
category slug:
encyclopedia
description:
Vaccine against COVID-19
original url:
https://en.wikipedia.org/wiki/Sinopharm_CNBG_COVID-19_vaccine
date created:
date modified:
2024-01-24T12:17:43Z
main entity:
{"identifier":"Q110291641","url":"https://www.wikidata.org/entity/Q110291641"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/94/Coronavirus._SARS-CoV-2.png","width":2048,"height":2048}
fields total:
13
integrity:
15